Dopamine D2 receptor imaging and measurement with SPECT

Area of Science:

• Neuroscience
• Radiochemistry
• Nuclear Medicine

Background:

• Visualizing dopamine D2 receptors in the living human brain is now possible using SPECT and an [123I]-labeled ligand.
• S(-)IBZM exhibits high affinity and specificity for D2 receptors, making it suitable for imaging studies.
• Extrapyramidal disorders are associated with alterations in dopamine receptor function.

Purpose of the Study:

• To quantify dopamine D2 receptor density in the human brain using SPECT imaging.
• To investigate changes in D2 receptor binding in patients with Parkinson's disease and other extrapyramidal disorders.
• To assess the impact of dopaminergic therapy on D2 receptor availability.

Main Methods:

• Administration of [123I]-labeled S(-)IBZM (5mCi) intravenously.
• Data acquisition using a rotating double-head scintillation camera between 60 and 110 minutes post-injection.
• Semiquantitative analysis calculating the ratio of striatal counts to frontal cortex counts as an index of D2 receptor density.

Main Results:

• A significant age-related decline in D2 receptor binding was observed in controls and Parkinson's disease (PD) patients.
• PD patients on dopaminergic therapy showed significantly lower D2 receptor binding ratios, suggesting receptor downregulation.
• Hemiparkinsonian patients exhibited higher D2 receptor binding on the contralateral side, indicating receptor supersensitivity.
• Severely reduced D2 receptor binding was found in patients with progressive supranuclear palsy, multiple system atrophies, and Huntington's disease.

Conclusions:

• SPECT imaging with [123I]-S(-)IBZM is a valuable tool for assessing D2 receptor availability in vivo.
• Dopaminergic therapy may lead to D2 receptor downregulation in Parkinson's disease.
• D2 receptor imaging can help differentiate between various neurodegenerative disorders affecting the basal ganglia.